Alcon and AZ sign ophthalmology research deal

by Admin 31. July 2009 15:42

Alcon has entered into a five-year research agreement with AstraZeneca that gives Alcon exclusive ophthalmic drug discovery and potential development rights to AstraZeneca’s compound library.

The two companies are targeting the development of drugs to treat sight-threatening conditions such as glaucoma, wet and dry age-related macular degeneration and other retinal diseases, as well as ocular allergy, dry eye and other inflammatory eye conditions.

“Alcon and AstraZeneca share a common goal: to use leading-edge science to deliver medicines that will benefit patients,” said Jan Lundberg, AstraZeneca’s Executive Vice President of Global Discovery Research. “We are constantly looking for new opportunities to maximise our strong early pipeline, and this collaboration is proof of its value beyond the therapy areas for which AstraZeneca is renowned.”

Under the terms of the agreement, Alcon obtains immediate access to thousands of AstraZeneca compounds in a variety of drug classes. AstraZeneca will hand over development and regulatory documentation associated with each compound as relevant to ophthalmology.

Alcon will perform and fund all R&D activities to move selected compounds forward. Individual licence agreements will be negotiated on a case-by-case basis for any compound that moves into clinical development, including regulatory milestone payments and royalties on product sales.

“This strategic partnership represents an extraordinary opportunity to bring Alcon’s global leadership in the field of ophthalmology together with AstraZeneca’s world-class basic research capability to advance treatments in eye care,” said Kevin Buehler, Alcon’s President and Chief Executive Officer. “I believe this partnership will not only benefit both parties, but will also lead to new therapies that reduce the incidence of blindness around the world.”

Tags:

News

Selling in a multicultural world

by Admin 31. July 2009 15:32

Conducting business across cultural boundaries can sometimes lead to accidental faux pas. Intercultural trainer Paul Stiff explains how encouraging your team to be sensitive to cultural differences could result in improved business relationships.clip_image001

As a result of the globalisation of labour and the demands of the NHS in the past few decades, we have seen an influx of nurses, medical staff, doctors and surgeons from a vast array of internationally distinct cultural backgrounds into the UK.

There are many outstanding examples including Professor Sir Magdi Yacoub, the world-renowned cardiac surgeon and a pioneer in the field of heart and lung transplantation. A Coptic Christian Egyptian by birth, he has performed more transplants than any other surgeon in the world. Indian National, Professor Ara Darzi, who pioneered innovative work in the development of minimally invasive surgery, is also another notable example, as is Ms. Sunita Shrotria, also originally from India, who pioneered scarless surgery for the treatment of breast cancer.

Thanks to this trend, many important advances in modern medical practices have been made, which, in turn, have offered hope to many British people through those that have chosen to live and work in the UK. In fact, the international excellence that British medicine enjoys today is believed by many to be due to the historical moves made by Jewish members of the medical profession from mainland Europe and Russia, leaving religious persecution in their own countries and settling, studying and researching here. In turn, their families trained and contributed much to this country to become the doctors we know and respect today.

However, these trends taken together have also resulted in the nature of a medical representative’s customer base changing gradually over the years. Whether it is appreciated or not, there is now a complex interaction between buyers and sellers of medical products which often has less to do with features and benefits and more to do with the level of cultural understanding between the people undertaking the transaction.

 

Relationship before business

It is easy to dismiss cultural differences when customers originating from countries as far afield as Iraq, Afghanistan, South Africa or Pakistan are all fluent in the English language. However, don’t be misled. Although understanding between cultures is all about communication, it has, in fact, very little to do with language. Culture is a form of mental mindset, a form of pre-programming, which needs to be understood as distinct from linguistic communication.

One of the key cultural differences to become aware of is the fact that in countries outside Northern Europe people tend to be ‘people people’, rather than ‘process people’. They are relationship driven and value the nature, quality and depth of the relationship as much as, if not more than, the intellectual content delivered by that relationship. Outside Northern Europe, it is essential to build trust and understanding over time before consideration is given to business transactions. This ingrained cultural aspect does not change because of a different location or because your counterpart speaks perfect English – it travels with the person.

The need for relationships before business is initiated contrasts with the British culture, which is more knowledge driven. Generally, this is where issues arise because such cultural aspects are so often deeply ingrained we don’t even realise they are there. It is frequently observed within the context of the world outside Northern Europe that it is impossible to do business with people you don’t know and therefore cannot trust.

 

Cultural empathy

Our society works because we assume the majority of our tribe have the same beliefs and values as us. When we come across another culture, basic differences become all too apparent – often too late and when the relationship has faltered. Therefore, to be successful in an increasingly multicultural world, it is important to develop an attitude of cultural empathy and understanding that extends to the many different cultural ‘shapes’ we come across in our every day work. Achieving this and then adapting our own personal style to ‘fit in’ and demonstrate such understanding with another culture – by even just a small degree – will often make a significant difference in the eyes of a colleague or customer and help build that all important relationship.

Religion is very often key, and its importance to many in this country is made even starker as a contrast when set against the secular and humanistic values in Northern Europe.

Understandable examples might include a Muslim doctor who is fasting during the Holy Month of Ramadan. This year Ramadan falls in mid-August and it would be inappropriate to offer to meet over a sandwich or a drink when fasting will be observed during the long daylight hours of the UK summer. Similarly, many Greeks, Russians and Egyptians are Orthodox Christians and celebrate Christmas and Easter on different dates to that of the majority of UK residents. Wishing an Orthodox Christian ‘Happy Easter’ at the right time shows you understand that person’s different emotional drivers.

 

Attitudes and understanding

Religion is just one aspect of culture which needs to be considered and often it is mis-understanding or ignorance of more subtle drivers that can contribute towards the non-success of a relationship.

For example, attitudes towards age – particularly related to level of responsibility – can differ markedly between cultures. In the UK, for example, the age of the person in charge is generally irrelevant and position is normally associated with merit. However, in Middle Eastern and Asian cultures, responsibility and respect is directly connected to age and irreverence to this cultural point may accidentally offend.

Hierarchy is also a deeply ingrained aspect of many cultures. Asking a senior person from Malaysia – one of the most hierarchical countries in the world – what they think during a meeting could cause acute embarrassment if they were unsure of the answer.

The social background of the person in their home country is also a consideration which should be kept in mind, as it is often very different from their position UK society. Some years ago, I knew of a colleague who had worked with a young Arab paediatrician who was part of the ruling family of a very notable, prominent Gulf State. Though anglicised through her Western upbringing and specialisation at some of London’s leading teaching hospitals, she was indeed ‘her Highness’ in her own country and being aware of that here in the UK was appropriate.

It is also necessary to be aware and tread carefully around political bias. In the ‘global’ world, it is often easy to come across as ill-informed or naive with our tendency to pigeon-hole or over-simplify attitudes towards certain situations. However, be sure not to ‘ignore the elephant in the room’. If you are working with an Indian doctor make sure you are up to date about the recent problems in Mumbai, for example, as thoughts of home will often be on his or her mind.

Punctuality is also an interesting point. In the UK, good time-keeping is highly valued, though in many cultures, such as those in Southern Europe, punctuality is not a given. The good news is that the importance of punctuality will increase in proportion with the strength of a relationship built over time.

 

Meeting the culture challenge

The sales and marketing of pharmaceutical products in the UK increasingly involves the need to work with people from different cultures and backgrounds. This brings with it a set of cultural and communication challenges that need to be addressed if the business outcome is to be successful. One of the key reasons for this is failing to take into account the invisibility of our own culture.

Quite simply, not only is the world outside our own quite extraordinary, it is, at times, too extraordinary for us to even imagine. Conducting business across cultural boundaries can create difficulties, however, it is these hurdles that make working with people from different cultures so challenging and interesting at the same time. The key to success is to learn about the culture of person you are doing business with.

Paul Stiff is Intercultural trainer at Farnham Castle International Briefing & Conference Centre. Farnham Castle specialises in cross cultural management development programmes and international assignment briefings for every country in the world in addition to those coming to live and work in Britain. Tel: 01252 720406, web: www.farnhamcastle.com.

Tags:

Features

Changes in device use accelerated by Web 2.0

by Joel Lane 30. July 2009 17:32

New technologies for spreading information are greatly increasing the pace at which health organisations respond to clinical data on device usage, according to a new study.

Researchers writing in the US journal Circulation: Cardiovascular Quality and Outcomes found that the use of search engines, smart phones and other new technologies led to strikingly rapid changes in clinical practice following studies of drug-eluting stents (DES).

According to Matthew T. Roe, M.D., lead author of the study, the very rapid worldwide spread of medical data means that studies presented at medical conferences can have an almost instant impact on patient treatment.

Researchers examined the impact on clinical practice of studies presented in September 2006 that found DES use to be associated with a higher risk of late stent thrombosis. The use of DES fell from 90% of patients who received coronary stents to 67% in six months, then to 58% in the following nine months. "To our knowledge, this was the most rapid change in practice patterns in cardiology," Roe said.

The report concluded that the rapid spread of information through electronic media may become the "predominant stimulus for changes in practice in the future".

Clyde W. Yancy, M.D., President of the American Heart Association, commented: "The opportunity to widely share important findings that promptly impact practice is becoming a powerful tool to drive change. The requirements for prompt but thorough peer review and nimble responsiveness to new data are evident. Managing this new health IT space will require focus, assessment and realignment."

taxusexpress2

Taxus Express stent

Tags:

Medtech News

Arrow Medical appoints new MD

by Joel Lane 30. July 2009 17:24

Rita Didcock has been appointed Managing Director at Arrow Medical Ltd, one of Britain's leading specialist contract medical device manufacturers.

Rita will manage the company's facility at Kington, Herefordshire, working with Graham Jarrett as CEO and John Johnson as New Product Development Director.

Rita has worked with Arrow Medical for more than 12 years, and has been Production Director since 2006. She succeeds John Johnson, who will continue to play a role in sales support at board level.

Recently, Rita played a critical role in increasing Arrow Medical's cleanroom production capacity and paving the way for manufacture of Class III medical devices, including implantable and invasive devices such as catheters. She also led production of a number of 'life-critical' theatre, anaesthesia, ventilation and air and fluid management components.

Graham Jarrett commented: "Arrow Medical has faced and overcome a number of major business challenges in the last few years. I am very pleased to congratulate Rita on her promotion, and pay tribute to John for his excellent contribution to the business during 20 years as Managing Director. I look forward to working with both of them as Arrow Medical continues to make headway in a very competitive and demanding contract medical manufacturing world."

Arrow Medical manufactures a wide range of components used in anaesthesia, orthopaedics, cardiology, inflatable medical products and fluid and air management by medical device companies worldwide.

Arrow Medical, Kington, Herefordshire - - 8.7.09



Picture by Antony Thompson - Thousand Word Media, NO SALES, NO SYNDICATION contact for more information mob: 07775 556610 web: www.thousandwordmedia.com email: antony@thousandwordmedia.com



The photographic copyright (© 2008) is exclusively retained by the works creator at all times and sales, syndication or offering the work for future publication to a third party without the photographer's knowledge or agreement is in breach of the Copyright Designs and Patents Act 1988, (Part 1, Section 4, 2b). Please contact the photographer should you have any questions with regard to the use of the attached work and any rights involved.

Rita Didcock

Tags:

Medtech News

Novozymes’ Chief Scientist honoured

by Admin 30. July 2009 15:43

 Geoffrey Francis, Chief Scientist at Novozymes Biopharma, has been named one of the 100 most inspiring people by PharmaVOICE magazine in recognition of his influence on the life sciences industry.

The PharmaVOICE 100 were nominated by PharmaVoice readers, who identified the individuals they believe have the greatest influence and positive impact on corporate leadership, research and development, technology, creativity, marketing and business strategies.

“It’s a great honor to have been recognised by my peers and to be profiled alongside such an esteemed group of industry leaders,” commented Geoffrey Francis. “I am delighted that this honor validates Novozymes Biopharma’s mission and is a real testament to the outstanding team we have here.”

Geoffrey Francis’ nomination and selection to the PharmaVOICE 100 was based on his exceptional 30-year career in the life sciences and biotechnology industries and his ability to inspire and motivate those around him.

With specific expertise in drug discovery, protein expression, cell biology, animal physiology and protein biochemistry, Geoffrey has a long and successful career in senior management and research within government, academia and industry.

Geoffrey used his expertise as part of the team to found the Cooperative Research Centre for Tissue Growth and Repair, Adelaide in 1991 and held senior scientist positions at CSIRO Human Nutrition and GroPep Ltd before joining Novozymes Biopharma in 2006.

Editor-in-chief and co-founder of PharmaVOICE Taren Grom said: “The PharmaVoice 100 are individuals who think outside the box, pioneer new paths to success, and inspire their colleagues in the industry; they translate industry issues into opportunities and take the time to mentor the next generation of leaders in the life sciences arena.”

Tags:

News

Budgeting for radical change

by Admin 30. July 2009 11:00

Budget cuts could bring an acceleration in the adoption of private sector service providers. Mike Sobanja and Andy Etheridge ask whether the industry has the skills to influence these new customers.    

As senior decision makers across the NHS are now considering the implications of expected budget cuts from 2011, probably in tandem with a new political agenda resulting from the forthcoming general election, it is essential that pharma companies recognise the potential impact on prescribing practice. Both political change and a need to deliver upwards of 3-6% savings per annum is likely set to accelerate the process of using private sector organisations to deliver services in both primary and secondary care across England. Furthermore, strategies such as the delivery of care closer to patients’ homes are expected to be reinvigorated and re-budgeted. However, whilst it is essential to understand the organisational motivation and practices of different private sector organisations, from the commercial to the social enterprise companies, pharma companies must not forget the underlying goal. The objective is not simply to understand behaviour but to deliver the right messaging, in the right way to achieve quantifiable behavioural change.  

Financial driver

Is the pharmaceutical industry ready for the forthcoming changes set to sweep the NHS – at least in England? Whilst much of the structure of the NHS has changed significantly in recent years, it is fair to say that some expected changes, such as the growing adoption of private sector service delivery in both primary and secondary care and the move to deliver more patient care at home, have failed to materialise to the expected degree. Indeed, the question remains as to just how committed this government has been to using the private sector as an alternative source of supply. Has, in fact, the strategy been simply an opportunity to leverage the market and provide stimulus to mainstream NHS providers within the health service? Or, is it that the evolution towards greater adoption of private sector services has been constrained by the imbalance of power between commissioners and providers – particularly hospitals? With the NHS now facing a massive budgetary financial challenge for 2011-2014, it is reasonable to assume that many organisations will be taking a much closer look at the economics of private sector service delivery – especially if backed by a change in government to one far more commercially focused. The latest formal position from the Department of Health states that during the three years from 2011, the NHS will make a contribution to the Treasury of £15-£20 billion. This will create pressure to squeeze efficiency to attain around 3% efficiency savings, which is expected to result in an escalation in private sector service delivery.  

Different models

Of course this private sector opportunity only applies within England – Scotland has now outlawed the use of private companies to provide services, such as General Practitioners, whilst Wales and Northern Ireland are not encouraging the strategy. In England, however, it is likely that there will be an acceleration in the adoption of private sector service providers. To date, some 150 general practitioner practices have been let to the private sector, ranging from organisations such as Aetna Healthcare and United Healthcare, to a wave of traditional NHS practices that have opted to move from the traditional GP partnership to become limited liability partnerships or private companies. In addition, there are a growing number of social enterprise organisations, including Community Interest Companies (CICs), all operating under different models, including not for profit. This latter model, in particular, is likely to grow as a result of government support and stimulus to market conditions and contract terms. For pharma companies the fast evolving mix of private organisational types opens up a raft of new business practices and operational models to understand – all of which are very different to the traditional NHS model and culture. The one size fits all approach to dealing with the customer has now become even less relevant. Understanding both organisational drivers, which range from the highly commercial to socially oriented, and that the types of people involved in these organisations will also differ considerably to traditional NHS GPs is essential. It will also be key to track the changing attitudes to prescribing: while these providers are not accountable to either politicians or the Department of Health, each will have a contract with commissioners that will specify compliance to PCT policies, including formularies.  

Local care

Private sector organisations, including pharma companies, may also have a growing part to play in delivering patient care outside hospitals and within the community. Whilst, again, this is a strategy that has yet to achieve serious adoption, there are clear demonstrations of its value – in some areas upwards of 95% of Type II diabetes cases are now managed in the community, for example. There is also evidence that care pathways are being redesigned to organise care around patient needs, which could result in a reduction of on outpatient visits within some PCTs. However, there is also evidence that providing care closer to patients’ homes is not necessarily cheaper, due to the loss of economies of scale in hospital and the changes to payment structures which have escalated the cost of GP visits. As the pressure on costs grows, local NHS commissioners will probably revisit the cost/benefits of community-based care and assess the role of private providers. And a number of pharma companies are exploring potential service provider models. However, given the expected strong resistance to private sector involvement from both providers and communities in many areas, it is likely that pharma companies will do better with a less competitive model. By aligning with an existing provider and delivering essential business skills, as Sainsbury’s has achieved with GP surgeries by providing back office services, or SpecSavers for independent ophthalmic opticians, organisations can gain a foothold in this marketplace. This strategy has far more chance of success than any attempts at entering the market independently.  

Conclusion

It has been evident for the last couple of years that the pharma industry has got to stop treating the NHS as a single organisation. Now, as budgetary pressure and potential political change come into effect, those organisations failing to understand the range of bodies that operate within it could discover the customer base has moved very radically and is behaving in very different ways. However, the emphasis must not just be on understanding the changing behaviour but on influencing that change to achieve objectives. Understanding the NHS customer supply chain, identifying both customers and that customer’s customer is key to not only identifying the chain of influence but also to being more sophisticated about following those chains of influence to affect behaviour and prescribing practice.    

Andy Etheridge is Commercial Director for Direct Marketing at Cegedim Dendrite. Cegedim Dendrite has over 35 years experience in providing value added information, CRM and Marketing solutions to the pharmaceutical industry. Mike Sobanja is Chief Executive of the NHS Alliance – the independent body that represents NHS primary care. Values-based, the NHS Alliance is the only organisation that brings together PCTs with GP practices, clinicians with managers and board members, and NHS primary care with its patients. The NHS Alliance membership and its national executive are fully multi-professional.

Tags: ,

Features

BloodTrack reduces risk and waste

by Joel Lane 29. July 2009 17:54

A system for remote allocation of blood has enabled three London hospitals to comply with new MHRA safety regulations and to minimise waste.

The installation of five BloodTrack HemoNine remote issue blood refrigerators means that the Barts and The London NHS Trust can directly access blood from refrigerators on the wards, without the blood bank having to prepare and transport specific units.

This system has enabled the Trust to save on blood stock, staff time and overall costs across its three hospitals.

BloodTrack HemoNine from Olympus UK is a locking refrigerator for securely dispensing blood in remote locations such as operating theatres. Blood can be remotely allocated and then automatically dispensed, assigned and labelled for the patient at the refrigerator.

Matthew Grantham, Transfusion Laboratory Manager at Barts and The London, said: "BloodTrack HemoNine provides clinical staff immediate access to blood products as and when it is required, when patients really need it. The nurses love having the ability to issue blood on demand, especially in A&E where the system sits in the resuscitation area."

At The London Chest Hospital, the new system has significantly reduced blood inventory and staff time. Before the system was installed, blood was transported by taxi to clinical sites up to two miles away. Blood products were often over-requested 'in case'.

Chris Broomhead, Consultant Anaesthetist at the Barts and The London, commented: "Since the BloodTrack HemoNine has been introduced, we have reduced our blood usage in cardiothoracic surgery over the last 6 months by approximately 10%. The process of administering blood has become faster and more efficient, with reduced blood wastage."

For more details, visit www.olympuspatientsafety.co.uk.

Tags:

Medtech News

Minimally invasive device for bariatric surgery launched

by Joel Lane 29. July 2009 17:50

UK company Surgical Innovations is launching a new flexible laparoscopic device for weight loss surgery.

The new device, which was developed in collaboration with laparascopic surgeons, will be unveiled at the International Federation for the Surgery of Obesity and Metabolic Disorders in Paris.

The LogiFlex offers bariatric surgeons an improved solution for gastric banding procedures. It is made from a combination of single-use and reusable components, enhancing performance and cost-effectiveness.

The flexible tip of the device features a 'cut down' profile, allowing easy insertion through the retro gastric tunnel. Individual patented tip options provide a bespoke solution for each gastric band manufacturer. The LogiFlex also incorporates a slot design that provides a grip on the suture, allowing the gastric band to be drawn into position more easily.

Graham Bowland, Managing Director of Surgical Innovations, said: "LogiFlex's design is based on our highly successful Endoflex, which is still the world's leading laparoscopic device for liver retraction. Our flex technology has been utilised by many other companies. Now we are delighted to announce our development of a more advanced flex technology product and are looking forward to unveiling it at this prestigious event."

Leeds-based Surgical Innovations supplies equipment for minimally invasive surgery and autologous blood transfusion.

For more details, visit www.surginno.com.

LogiFlex 2

LogiFlex

Tags:

Medtech News

New surgery kit gives blind bears sight

by Joel Lane 29. July 2009 17:45

A new technology for cataract surgery has enabled a team of vets to restore the sight of rescued moon bears in China.

The new phaco-emulsification kit is a light, portable technology that makes cataract surgery on large animals much more practical.

Claudia Hartley and David Donaldson from the UK's Animal Health Trust charity (AHT) operated on ten bears at the Moon Bear Rescue Centre in Chengdu, China to remove cataracts or correct vision.

Moon bears (or Asiatic black bears) are rescued from bear bile farms in China, where their bile is milked for use in medicines. They are kept in coffin-sized cages and denied regular food or water, which often leads to eye disease and other health problems.

Snoopy, one of the bears operated on, was diagnosed blind in 2003 with severe cataracts in both eyes. Six years later, the AHT team were able to restore her vision.

"On my first visit I saw several bears I knew I could help," said Claudia Hartley. "However the difficulty of getting heavy and cumbersome equipment to China for the surgeries made it virtually impossible.

"This new machine changes that. With it we've already given sight back to bears who have suffered immeasurably. The kit really will revolutionise the way we can treat eye disease in larger animals."

The phaco-emulsificaton kit will also make it possible to control equine recurrent uveitis, the most common cause of blindness in horses, through an operation known as vitrectomy. The AHT is the first place in the UK to offer this treatment to horses.

Claudia added: "This machine will help restore sight to many animals. It's an incredible development for ophthalmologists across the world."

Snoopy now_hay_7 

Snoopy (photo © Animals Asia Foundation)

Tags:

Medtech News

Success for first Cancer Congress Update

by Admin 29. July 2009 15:40

The 2009 Cancer Congress Update has been hailed a success by clinicians from the worlds of breast, colorectal, lung, prostate and haematological cancer.

Created by medical education agency Succinct Healthcare Communications, the event was designed to provide a UK-focused digest of highlights from the past year’s international oncology meetings, and to act as a forum for discussion to facilitate translation of the data into clinical practice.

The unusual cross-sector audience allowed clinicians to share their experiences and research with professionals treating other cancers.

Dr Mark Verrill of the North East Cancer Network said: “The Cancer Congress Update has been a great meeting. We all usually talk to people who treat the same cancers as ourselves, and it has been fascinating to see the amount of commonality between different tumours. The congress has brought us into one big cancer family.”

Sponsored by AstraZeneca, Novartis, Roche, sanofi-aventis and Teva Hospitals, the Cancer Congress Update acted as a comprehensive resource for those unable to attend meetings such as ASCO 2009 and SABCS 2008.

The Managing Director of Succinct Healthcare Communications, Sean McGrath, added: “This was a fantastic opportunity for specialists to exchange ideas on emerging trends with a panel of experts. We are already planning next year’s event and hope that it will help to deliver the right cancer drugs to the patients who need them faster than ever before.”

Tags:

News

TextBox

Tag cloud

Calendar

<<  May 2013  >>
MoTuWeThFrSaSu
293012345
6789101112
13141516171819
20212223242526
272829303112
3456789

View posts in large calendar